Cargando...
Anti-GD2 mAbs and next-generation mAb-based agents for cancer therapy
Tumor-specific monoclonal antibodies (mAbs) have demonstrated efficacy in the clinic, becoming an important approach for cancer immunotherapy. Due to its limited expression on normal tissue, the GD2 disialogangloside expressed on neuroblastoma cells is an excellent candidate for mAb therapy. In 2015...
Gardado en:
| Publicado en: | Immunotherapy |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Future Medicine Ltd
2016
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5619016/ https://ncbi.nlm.nih.gov/pubmed/27485082 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/imt-2016-0021 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|